Novo Nordisk's Next-Gen Weight-Loss Drug CagriSema Deemed 'Obsolete' After Disappointing Trial Results

Shares of Novo Nordisk, owner of Wegovy and Ozempic, fell sharply after its highly anticipated next-generation weight-loss drug, CagriSema, failed to meet investor expectations in testing, leading it to be branded 'obsolete'.

23 Feb, 14:26 — 23 Feb, 14:26

Post Share

ℹOnly 1 source covers this story

Read at source (1 outlet)

The Guardian1d ago

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’

Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations Business live – latest updates The owner of Wegovy and Ozempic has suffered a significant setback, as its highly anticipated new weight-loss treatment was labelled “obsolete” after disappointing clinical trials. Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish firm’s CagriSema drug fell short of investors’ expectations. Continue reading...

By Julia Kollewe

Read full article →

PERSPECTA

PERSPECTA

Novo Nordisk's Next-Gen Weight-Loss Drug CagriSema Deemed 'Obsolete' After Disappointing Trial Results

Read at source (1 outlet)

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’

Related Stories

Prayer march marks start of 40th People Power anniversary events

Philippine Supreme Court Clarifies 'Plain View' Not Required for Searches During Lawful Arrests

Bill Filed to Bar Firms Linked to Public Officials from Government Deals in Philippines

Bayan calls for Marcos Jr. accountability in flood control mess

PERSPECTA